The FDA Just Cut Psilocybin’s Review to Two Months — and the Drug Was Never the Slow Part

Ten to twelve months. That’s how long the FDA normally sits with a new drug application before it says yes or no. Compass Pathways is now looking at something closer to eight weeks.

That compression is real: FDA Commissioner Marty Makary gave Compass’s synthetic psilocybin program, COMP360, a fast-lane pass that pulls its application to the front of the queue and puts senior staff on it immediately — what the agency calls a National Priority Voucher. It’s one of three such vouchers issued after an April 2026 executive order told federal agencies to speed up psychedelic drug review. Compass is the furthest along of the three.

A two-month FDA review for a Schedule I compound is not a rubber stamp — it’s a bet the agency is making on data that already looks unusually strong, and the part worth watching isn’t whether the drug works.

If you’ve done two or three rounds of antidepressants, sat through months of talk therapy, and the standard drugs have already failed you — what clinicians label treatment-resistant depression — you’ve probably stopped believing timelines matter. This one might.

The data behind the fast lane

Compass isn’t leaning on the voucher alone. On August 5, the company reported six-month data from its second large late-stage trial — the last and biggest hurdle a drug clears before regulators decide it’s real medicine, not just a promising early result, known as a Phase 3 trial. The response held at six months, not just at the two-week mark psychedelic studies usually get remembered for. Compass also said 90% of surveyed psychiatrists would prescribe COMP360 in its first year if approved, and it’s filing its application in pieces as sections finish — a rolling NDA — targeting completion in Q4 2026 and a launch in the first half of 2027, backed by $433 million in cash on hand.

Where the caution actually belongs

The speed isn’t the risk to the drug. It’s a risk to everything around the drug. COMP360 isn’t a pill you take home — it’s delivered inside a supervised session with trained clinical staff, and that infrastructure, not FDA paperwork, is what actually takes years to build. Bloomberg’s Opinion desk warned in April that political enthusiasm for psychedelic medicine, including from the White House, is running ahead of the evidence in some corners of this field — and Compass isn’t the only place that enthusiasm shows up. Nature reported the FDA separately cleared an early trial for a noribogaine compound for alcohol use disorder, while Texas alone has committed $100 million to ibogaine research. Not every program in this rush carries six-month durability data. Compass does. The voucher doesn’t distinguish between the two.

What should worry you isn’t a bad drug getting approved fast. It’s a good drug getting approved before insurers, training programs, and enough facilitators exist to get it to people who’ve already run out of options.

Naloxone is still free at your local health department tonight, no prescription required. That doesn’t change while any of this plays out.